Skip to Content

Rule

Institutional Review Boards; Correcting Amendments

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; correcting amendments.

SUMMARY:

The Food and Drug Administration (FDA) is amending its regulations regarding institutional review boards to address a minor correction to the regulatory text and to update contact information. This action is editorial in nature and is intended to provide accuracy and clarity to the Agency's regulations.

DATES:

This final rule is effective March 15, 2013.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Kathleen Pfaender, Office of Special Medical Programs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5172, Silver Spring, MD 20993, 301-796-8346.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

FDA is amending 21 CFR part 56 to correct a minor error in the Code of Federal Regulations (CFR), and to update obsolete information. A minor spelling error was introduced inadvertently in the CFR when the regulations were first published. Also, contact information in the regulations is obsolete and in need of updating.

Publication of this document constitutes final action under the Administrative Procedures Act (5 U.S.C. 553). FDA has determined that notice and public comment are unnecessary because this amendment to the regulations provides only technical changes to correct minor errors and to update obsolete information, and is nonsubstantive.

Start List of Subjects

List of Subjects in 21 CFR Part 56

  • Human research subjects
  • Reporting and reporting requirements, and Safety
End List of Subjects

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 56 is amended as follows:

Start Part

PART 56—INSTITUTIONAL REVIEW BOARDS

End Part Start Amendment Part

1. The authority citation for 21 CFR part 56 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 343, 346, 346a, 348, 350a, 350b, 351, 352, 353, 355, 360, 360c-360f, 360h-360j, 371, 379e, 381; 42 U.S.C. 216, 241, 262, 263b-263n.

End Authority Start Amendment Part

2. In § 56.106 revise paragraph (d) to read as follows:

End Amendment Part
Registration.
* * * * *

(d) Where can an IRB register? Each IRB may register electronically through http://ohrp.cit.nih.gov/​efile. If an IRB lacks the ability to register electronically, it must send its registration information, in writing, to the Office of Good Clinical Practice, Office of Special Medical Programs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5129, Silver Spring, MD 20993.

* * * * *
Start Amendment Part

3. Section 56.107 is amended in paragraph (a), by revising the 3rd sentence to read as follows:

End Amendment Part
IRB membership.

(a) * * * In addition to possessing the professional competence necessary to review the specific research activities, the IRB shall be able to ascertain the acceptability of proposed research in terms of institutional commitments and regulations, applicable law, and standards of professional conduct and practice. * * *

* * * * *
Start Signature

Dated: March 12, 2013.

Leslie Kux,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2013-06030 Filed 3-14-13; 8:45 am]

BILLING CODE 4160-01-P